Cancer Research Annual Meeting 2010  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 808, February 1, 2008. doi: 10.1158/0008-5472.CAN-07-3169
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, N.
Right arrow Articles by Gélinas, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, N.
Right arrow Articles by Gélinas, C.

Cell, Tumor, and Stem Cell Biology

Repression of B-Cell Linker (BLNK) and B-Cell Adaptor for Phosphoinositide 3-Kinase (BCAP) Is Important for Lymphocyte Transformation by Rel Proteins

Nupur Gupta1,2, Jeffrey Delrow5, Amar Drawid4,6, Anirvan M. Sengupta4, Gaofeng Fan1,2 and Céline Gélinas1,3

1 Center for Advanced Biotechnology and Medicine, 2 Graduate Program in Biochemistry and Molecular Biology, and 3 Department of Biochemistry, Robert Wood Johnson Medical School; 4 BioMAPS Institute for Quantitative Biology, Rutgers University, Piscataway, New Jersey; 5 Fred Hutchinson Cancer Research Center, Seattle, Washington; and 6 sanofi-aventis, Bridgewater, New Jersey

Requests for reprints: Céline Gélinas, CABM, 679 Hoes Lane, Piscataway, NJ 08854. Phone: 732-235-5035; Fax: 732-235-4466; E-mail: gelinas{at}cabm.rutgers.edu.

Key Words: Rel • NF-{kappa}B • transformation • BLNK • BCAP

Persistent Rel/nuclear factor-{kappa}B (NF-{kappa}B) activity is a hallmark of many human cancers, and the Rel proteins are implicated in leukemia/lymphomagenesis but the mechanism is not fully understood. Microarray analysis to identify transformation-impacting genes regulated by NF-{kappa}B's oncogenic v-Rel and c-Rel proteins uncovered that Rel protein expression leads to transcriptional repression of key B-cell receptor (BCR) components and signaling molecules like B-cell linker (BLNK), the B-cell adaptor for phosphoinositide 3-kinase (BCAP) and immunoglobulin {lambda} light chain (Ig{lambda}), and is accompanied by a block in BCR-mediated activation of extracellular signal-regulated kinase, Akt, and c-Jun-NH2-kinase in response to anti-IgM. The BLNK and BCAP proteins were also down-regulated in lymphoid cells expressing a transformation-competent chimeric RelA/v-Rel protein, suggesting a correlation with the capacity of Rel proteins to transform lymphocytes. DNA-binding studies identified functional NF-{kappa}B–binding sites, and chromatin immunoprecipitation (ChIP) data showed binding of Rel to the endogenous blnk and bcap promoters in vivo. Importantly, restoration of either BLNK or BCAP expression strongly inhibited transformation of primary chicken lymphocytes by the potent NF-{kappa}B oncoprotein v-Rel. These findings are interesting because blnk and other BCR components and signaling molecules are down-regulated in primary mediastinal large B-cell lymphomas and Hodgkin's lymphomas, which depend on c-Rel for survival, and are consistent with the tumor suppressor function of BLNK. Overall, our results indicate that down-regulation of BLNK and BCAP is an important contributing factor to the malignant transformation of lymphocytes by Rel and suggest that gene repression may be as important as transcriptional activation for Rel's transforming activity. [Cancer Res 2008;68(3):808–14]




This article has been cited by other articles:


Home page
Cancer Res.Home page
G. Fan, Y. Fan, N. Gupta, I. Matsuura, F. Liu, X. Z. Zhou, K. P. Lu, and C. Gelinas
Peptidyl-Prolyl Isomerase Pin1 Markedly Enhances the Oncogenic Activity of the Rel Proteins in the Nuclear Factor-{kappa}B Family
Cancer Res., June 1, 2009; 69(11): 4589 - 4597.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Dutta, G. Fan, and C. Gelinas
CAPER{alpha} Is a Novel Rel-TAD-Interacting Factor That Inhibits Lymphocyte Transformation by the Potent Rel/NF-{kappa}B Oncoprotein v-Rel
J. Virol., November 1, 2008; 82(21): 10792 - 10802.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.